Literature DB >> 21856780

Living with idiopathic pulmonary fibrosis: an in-depth qualitative survey of European patients.

Gadi Schoenheit1, Ian Becattelli, Alan H Cohen.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal lung disease of unknown origin. Despite recent advancements, the diagnosis and management of IPF remains a distinct clinical challenge; as a result, patients often experience considerable delays in receiving an accurate diagnosis and confusion regarding prognosis and the availability of treatment options. In order to gain further insights regarding patients' perspectives on the diagnostic process, disease education, emotional well-being, and quality of life, we conducted a qualitative in-depth survey among IPF patients in Europe. Patients with a physician-confirmed IPF diagnosis were recruited to participate in an in-depth interview conducted by a trained facilitator who used a qualitative topic guide. A total of 45 patients from 5 European countries participated in the survey. The median reported time from initial presentation to confirmed diagnosis of IPF was 1.5 years (range <1 week to 12 years); in 58% of cases there was a delay of >1 year between initial presentation and a confirmed diagnosis of IPF. Additionally, 55% of patients reported consulting ≥3 physicians before receiving an IPF diagnosis. Patient satisfaction with medical care and disease education appeared to be higher among patients who were receiving care at a recognized center of excellence. Patients generally had reasonable expectations regarding the goals of therapy, with most recognizing the irreversibility of the disease and the limited prospects for achieving a cure. The most common unmet needs cited by participants were disease education resources, access to centers of excellence, and familial support programs. Our findings suggest that patients with IPF commonly experience protracted delays in receiving an accurate diagnosis and generally perceive the level of medical care as suboptimal, despite expressing reasonable expectations regarding the goals of therapy. These results support the need for further improvement in the areas of diagnosis, disease management, and patient education.

Entities:  

Mesh:

Year:  2011        PMID: 21856780     DOI: 10.1177/1479972311416382

Source DB:  PubMed          Journal:  Chron Respir Dis        ISSN: 1479-9723            Impact factor:   2.444


  43 in total

1.  Impact of an interstitial lung disease service in the diagnosis and management of interstitial lung disease in Singapore.

Authors:  Gin Tsen Chai; Teck Choon Tan; Yeong Shyan Lee; Gregory Jl Kaw; Khoon Leong Chuah; Yi Jing Lim; John Arputhan Abisheganaden; Bernard Yh Thong
Journal:  Singapore Med J       Date:  2019-07-11       Impact factor: 1.858

2.  Palliative care and location of death in decedents with idiopathic pulmonary fibrosis.

Authors:  Kathleen O Lindell; Zhan Liang; Leslie A Hoffman; Margaret Q Rosenzweig; Melissa I Saul; Joseph M Pilewski; Kevin F Gibson; Naftali Kaminski
Journal:  Chest       Date:  2015-02       Impact factor: 9.410

Review 3.  Optimizing quality of life in patients with idiopathic pulmonary fibrosis.

Authors:  Mirjam J G van Manen; J J Miranda Geelhoed; Nelleke C Tak; Marlies S Wijsenbeek
Journal:  Ther Adv Respir Dis       Date:  2017-01-01       Impact factor: 4.031

4.  Translation and validation of the King's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch.

Authors:  Monique Wapenaar; Amit S Patel; Surinder S Birring; Ron T van Domburg; Eric Wp Bakker; Virginia Vindigni; C Magnus Sköld; Vincent Cottin; Carlo Vancheri; Marlies S Wijsenbeek
Journal:  Chron Respir Dis       Date:  2016-12-26       Impact factor: 2.444

5.  Calpain 1 regulates TGF-β1-induced epithelial-mesenchymal transition in human lung epithelial cells via PI3K/Akt signaling pathway.

Authors:  Wei-Jun Tan; Qiu-Yue Tan; Ting Wang; Min Lian; Li Zhang; Zhen-Shun Cheng
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

6.  Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health records.

Authors:  Dmytro Onishchenko; Robert J Marlowe; Che G Ngufor; Louis J Faust; Andrew H Limper; Gary M Hunninghake; Fernando J Martinez; Ishanu Chattopadhyay
Journal:  Nat Med       Date:  2022-09-29       Impact factor: 87.241

7.  The Unmet Educational Needs of Patients with Interstitial Lung Disease. Setting the Stage for Tailored Pulmonary Rehabilitation.

Authors:  Julie Morisset; Bruno-Pierre Dubé; Chris Garvey; Jean Bourbeau; Harold R Collard; Jeffrey J Swigris; Joyce S Lee
Journal:  Ann Am Thorac Soc       Date:  2016-07

Review 8.  Idiopathic pulmonary fibrosis: early detection and referral.

Authors:  Justin M Oldham; Imre Noth
Journal:  Respir Med       Date:  2014-04-04       Impact factor: 3.415

9.  Identifying the benefits and risks of emerging treatments for idiopathic pulmonary fibrosis: a qualitative study.

Authors:  John F P Bridges; Victoria Federico Paly; Elizabeth Barker; Dolly Kervitsky
Journal:  Patient       Date:  2015-02       Impact factor: 3.883

10.  Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis.

Authors:  Marlies S Wijsenbeek; Jan C Grutters; Wim A Wuyts
Journal:  Adv Ther       Date:  2015-07-15       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.